Rohde, Veit

[["dc.bibliographiccitation.firstpage","1611"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","1619"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Schäfer, Niklas"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Schlegel, Uwe"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Ronellenfitsch, Michael W."],["dc.contributor.author","Uhl, Martin"],["dc.contributor.author","Maciaczyk, Jaroslaw"],["dc.contributor.author","Grau, Stefan"],["dc.contributor.author","Schnell, Oliver"],["dc.contributor.author","Hänel, Mathias"],["dc.contributor.author","Krex, Dietmar"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Gerlach, Rüdiger"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Mehdorn, Maximilian"],["dc.contributor.author","Tüttenberg, Jochen"],["dc.contributor.author","Mayer-Steinacker, Regine"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Brehmer, Stefanie"],["dc.contributor.author","Mack, Frederic"],["dc.contributor.author","Stuplich, Moritz"],["dc.contributor.author","Kebir, Sied"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Dunkl, Elmar"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Proescholdt, Martin"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Glas, Martin"],["dc.contributor.author","Steinbach, Joachim Peter"],["dc.date.accessioned","2020-12-10T18:41:29Z"],["dc.date.available","2020-12-10T18:41:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O-6-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ. Patients and Methods In this phase II, unblinded trial 182 patients in 22 centers were randomly assigned 2: 1 to BEV (10mg/kg every 2 weeks) during radiotherapy (RT) followed by maintenance BEV (10mg/kg every 2 weeks) plus IRI(125 mg/m(2) every 2 weeks) or to daily TMZ (75 mg/m(2)) during RT followed by six courses of TMZ (150-200 mg/m(2)/d for 5 days every 4 weeks). The primary end point was the progression-free survival rate after 6 months (PFS-6). Results In the modified intention-to-treat (ITT) population, PFS-6 was increased from 42.6% with TMZ(95% CI, 29.4% to 55.8%) to 79.3% with BEV+IRI (95% CI, 71.9% to 86.7%; P < .001). PFS was prolonged from a median of 5.99 months (95% CI, 2.7 to 7.3 months) to 9.7 months (95% CI, 8.7 to 10.8 months; P < .001). At progression, crossover BEV therapy was given to 81.8% of all patients who received any sort of second-line therapy in the TMZ arm. Overall survival (OS) was not different in the two arms: the median OS was 16.6 months (95% CI, 15.4 to 18.4 months) with BEV+IRI and was 17.5 months (95% CI, 15.1 to 20.5 months) with TMZ. The time course of quality of life (QOL) in six selected domains of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ)-C30 and QLQ-BN20 (which included cognitive functioning), of the Karnofsky performance score, and of the Mini Mental State Examination score was not different between the treatment arms. Conclusion BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ. However, BEV+IRI did not improve OS, potentially because of the high crossover rate. BEV+IRI did not alter QOL compared with TMZ. (C) 2016 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2015.63.4691"],["dc.identifier.eissn","1527-7755"],["dc.identifier.isi","000375309100011"],["dc.identifier.issn","0732-183X"],["dc.identifier.pmid","26976423"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77594"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","975"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","985"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Schäfer, Niklas"],["dc.contributor.author","Proescholdt, Martin"],["dc.contributor.author","Steinbach, Joachim P"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Grauer, Oliver"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Schlegel, Uwe"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Ronellenfitsch, Michael W"],["dc.contributor.author","Uhl, Martin"],["dc.contributor.author","Grau, Stefan"],["dc.contributor.author","Hänel, Mathias"],["dc.contributor.author","Schnell, Oliver"],["dc.contributor.author","Krex, Dietmar"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Tabatabai, Ghazaleh"],["dc.contributor.author","Mack, Frederic"],["dc.contributor.author","Schaub, Christina"],["dc.contributor.author","Tzaridis, Theophilos"],["dc.contributor.author","Nießen, Michael"],["dc.contributor.author","Kebir, Sied"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Glas, Martin"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.date.accessioned","2020-12-10T18:19:37Z"],["dc.date.available","2020-12-10T18:19:37Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/neuonc/nox204"],["dc.identifier.eissn","1523-5866"],["dc.identifier.issn","1522-8517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75313"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Schaefer, Nildas"],["dc.contributor.author","Steinbach, Joachim Peter"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Braun, Christian"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Gies, Martin"],["dc.date.accessioned","2018-11-07T09:40:06Z"],["dc.date.available","2018-11-07T09:40:06Z"],["dc.date.issued","2014"],["dc.identifier.isi","000358613202708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33436"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Clinical-Oncology"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0234956"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Krenzlin, Harald"],["dc.contributor.author","Bettag, Christoph"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Keric, Naureen"],["dc.contributor.editor","Ashkenazi, Itamar"],["dc.date.accessioned","2021-04-14T08:25:13Z"],["dc.date.available","2021-04-14T08:25:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0234956"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81555"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1932-6203"],["dc.title","Involuntary ambulatory triage during the COVID-19 pandemic – A neurosurgical perspective"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]